Work

Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration

Year: 2026

Type: article

Abstract: This post hoc analysis of 2 randomized clinical trials evaluates baseline and early treatment response factors associated with longer faricimab dosing intervals in patients with neovascular age-related macular degeneration.

Source: JAMA Ophthalmology

DOI: 10.1001/jamaophthalmol.2026.4385

Authors: Colin S. Tan, Benjamin Bakall, Adrian Hock Chuan Koh, Priya Vakharia, Deepak Sambhara, Mathias Maier, Quresh Mohamed, Ming Yang, Philippe Margaron, Shriji Patel, Eric H. Souied

Institutions: Tan Tock Seng Hospital, National Healthcare Group, University of Arizona College of Medicine- Phoenix, Eye & Retina Surgeons, Retina Vitreous Associates of Florida, TUM Klinikum, Gloucestershire Hospitals NHS Foundation Trust, Genentech, Roche (Switzerland), Université Paris-Est Créteil

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7222279423

FWCI:

Cites: 6

Cited by:

Related to: